The Latest Cardiac and Vascular News
ABBOTT PARK, Ill., July 13, 2020 /PRNewswire/ — Abbott (NYSE: ABT) announced today it has reached an agreement with Edwards Lifesciences Corporation to settle all outstanding patent disputes between the companies in cases related to transcatheter mitral and tricuspid repair products. The agreement will result in the dismissal of all pending cases or appeals […]
IRVINE, Calif., May 18, 2020 /PRNewswire/ — Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced that it has received CE Mark for the Edwards PASCAL transcatheter valve repair system for the treatment of European patients with tricuspid regurgitation (TR). “Although the […]
IRVINE, Calif., April 23, 2020 /PRNewswire/ — Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today reported financial results for the quarter ended March 31, 2020. First Quarter Results and Outlook Sales grew nearly 14% to $1.1 billion TAVR sales grew 24%; underlying1 sales grew 25% […]
IRVINE, Calif., Jan. 30, 2020 /PRNewswire/ — Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today reported financial results for the quarter ended December 31, 2019. Fourth Quarter Results and Outlook Q4 sales grew 20% to $1.2 billion; underlying1 sales grew 19% Q4 TAVR sales grew […]
NEW YORK, Dec. 5, 2019 /PRNewswire/ — Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, will discuss the company’s strategy for longer-term growth, provide an update on its technology pipeline and share its financial guidance during its annual investor conference today in New […]
IRVINE, Calif., Oct. 23, 2019 /PRNewswire/ — Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today reported financial results for the quarter ended September 30, 2019. Third Quarter and Recent Highlights Sales grew 21% to $1.1 billion; underlying1 sales grew 19% TAVR sales grew 26%; […]
SAN JOSÉ, Costa Rica, Oct. 10, 2019 /PRNewswire/ — Edwards Lifesciences Corporation, a world leader in innovations for structural heart disease and critical care monitoring aimed at patients, expanded its presence in Costa Rica with a $100 million investment and the addition of 500 new jobs by the end of 2020. The brand new facility is located […]
SAN FRANCISCO, Sept. 29, 2019 /PRNewswire/ — Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced new data demonstrating early and sustained health status advantages for severe aortic stenosis (AS) patients at low surgical risk treated with the Edwards SAPIEN 3 valve. […]
IRVINE, Calif., July 23, 2019 /PRNewswire/ — Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today reported financial results for the quarter ended June 30, 2019. Second Quarter and Recent Highlights Sales grew 15% to $1.1 billion; underlying1 sales grew 14% TAVR sales grew 16%; underlying […]
IRVINE, Calif., June 3, 2019 /PRNewswire/ — Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced that it has received notice of an unsolicited “mini-tender offer” by TRC Capital Corporation to purchase up to 1,000,000 shares, or approximately 0.48 percent of the […]
